

FORM PTO-1390 (Modified)
(REV 11-98)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES

44342.011800

DESIGNATED/ELECTED OFFICE (DO/EO/US)

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

CONCERNING A FILING UNDER 35 U.S.C. 371

09/646135

INTERNATIONAL APPLICATION NO.

PCT/JP99/01438

INTERNATIONAL FILING DATE

23.03.99 (23 March 1999)

PRIORITY DATE CLAIMED


24.03.98 (24 March 1998)

TITLE OF INVENTION

REMEDIES FOR HEPATITIS

APPLICANT(S) FOR DO/EO/US

Kazuko HIRABAYASHI and Junzo SEKI



Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 20 below concern document(s) or information included:

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ Certificate of Mailing by Express Mail
20. ☒ Other items or information:

WO99/48531

PCT/RO/101

09/646135

PCT/JP99/01438

44342.011800

The following fees are submitted:

CALCULATIONS PTO USE ONLY

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

- ☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$970.00
- ☒ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$840.00
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$690.00
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$840.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).

\$0.00

CLAIMS NUMBER FILED NUMBER EXTRA RATE

Total claims 3 - 20 = 0 x \$18.00

\$0.00

Independent claims 2 - 3 = 0 x \$78.00

\$0.00

Multiple Dependent Claims (check if applicable) ☐

\$0.00

TOTAL OF ABOVE CALCULATIONS =

\$840.00

Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). ☐

\$0.00

SUBTOTAL =

\$840.00

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).

\$0.00

TOTAL NATIONAL FEE =

\$840.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). ☒

\$40.00

TOTAL FEES ENCLOSED =

\$880.00

Amount to be:
refunded \$
charged \$

☒ A check in the amount of \$880.00 to cover the above fees is enclosed.

☐ Please charge my Deposit Account No. in the amount of to cover the above fees.
A duplicate copy of this sheet is enclosed.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 07-1855 A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Eugene C. Rzucidlo, Esq.
Greenberg Traurig LLP
885 Third Avenue, 21st Floor
New York, New York 10022

SIGNATURE

Eugene C. Rzucidlo

NAME

31,900

REGISTRATION NUMBER

DATE

2/ppts

09/646135
430 Rec'd PCT/PTO 08 SEP 2000
P-402 W0
3

SPECIFICATION

REMEDIES FOR HEPATITIS

TECHNICAL FIELD

The present invention relates to a therapeutic agent for hepatitis.

As used in this specification, the code "I" stands for inosinic acid, "C" for cytidylic acid, "A" for adenylic acid, and "U" for uridylic acid.

The terms "mismatched poly(I)•(C) and mismatched poly(A)•poly(U) mean th at poly(I)•(C) and poly(A)•poly(U) have double-stranded nucleic acid bases containing partly non-complementary nucleic acid, as well known in the art.


BACKGROUND ART

poly(I)•(C) is a double-stranded RNA consisting of polyinocinic acid and polycytidylic acid is broadly known to be a medicinally active substance having interferon-inducing activity and immunopotentiating activity.

It has recently been reported that interferon itself is effective in the treatment of hepatitis C (e.g., KAN-TAN-SUI, 9(4), 611 (1984); ibid., 13(1), 123 (1986); ibid., 12(5), 809 (1986); ibid., 23(5), 1065 (1991)). It is, however, difficult to treat hepatitis C with poly(I)•poly(C) capable of inducing interferon just by conventional administration methods, in view of the extent of interferon induction, toxicity, and the like.

On the other hand, there are known pharmaceutical- or drug-

carriers including those generally called cationic liposomes such as LIPOFECTIN (registered trademark) and those composed of a glycerol derivative such as 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoylglycerol of the following chemical formula [I] and a phospholipid as essential components [e.g. PCT WO91/17424, PCT WO94/19314].



The cationic liposome is considered to be a small vesicle composed of lipid bimolecular layer and charged positively in an aqueous solution. Since a cationic liposome becomes positively charged while a double-stranded RNA such as poly(I)·poly(C) negatively charged in an aqueous solution, a cationic liposome and poly(I)·poly(C), for instance, may easily form a complex when subjected to a typical dispersing treatment.

However, it is not known at all whether a complex of a double-stranded RNA such as poly(I)·poly(C) with a drug carrier like the above-mentioned cationic liposome would be effective in the treatment of hepatitis and the like.

DISCLOSURE OF INVENTION

The object of the present invention is to provide a novel medicinal agent useful in the treatment or the prevention of hepatitis.

The inventors of the present invention have found for the first

time that a complex of a double-stranded RNA such as poly(I)·poly(C) with a drug carrier like cationic liposomes are accumulated specifically in the liver and spleen and can induce interferon effective in the treatment of hepatitis etc. for a long time, and have established the present invention.

The present invention, in one aspect, provides a therapeutic or preventive agent for hepatitis (hereinafter, referred to as "the agent of the present invention") characterized in that it comprises a complex of a double-stranded RNA such as poly(I)·poly(C) with a cationic liposome. The complex will hereinafter be referred to as "the complex".

The present invention will be described in detail below.

The cationic liposome usable in the present invention includes LIPOFECTIN (registered trademark), LIPOFECTAMINE (registered trademark), LIPOFECTACE (registered trademark), DMRIE-C (registered trademark), or a drug carrier disclosed in PCT WO94/19314, e.g., the one composed of 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoylglycerol of the above-mentioned chemical formula [I] (hereinafter, referred to as "Compound A") and a phospholipid as essential components.

Examples of the preferred cationic liposome for the present invention include a drug carrier made from Compound A and a phospholipid, as essential components. The resultant drug carrier will hereinafter be referred to as "the carrier".

Examples of a double-stranded RNA usable in the present invention include poly(I)·poly(C), mismatched poly(I)·poly(C), poly(A)·poly(U), mismatched poly(A)·poly(U). Among them, the poly(I)·poly(C) is suitable.

The chain length of the above-mentioned double-stranded RNA is not particularly restricted, but it is suitable to be within the range of 50-2,000 base pairs (bp), preferably, 100 to 500 bp, more preferably, 200-400 bp. If the chain length of RNA is less than 50 bp, effectiveness would be insufficient, and if it is over 2,000 bp, the safety would be questionable. The chain length ranging from 100 bp to 500 bp is considered to be balanced range in connection with efficacy and safety. Likewise, as for the length of poly(I)·poly(C), 100-500 bp is preferred and 200-400 bp is still more preferred. Since the double-stranded RNA like poly(I)·poly(C), etc. usually exists with a given distribution of various chain lengths, the above-mentioned chain length indicates the base pair numbers of the largest distribution and is herein referred to as "mean chain length".

The phospholipid in the carrier is not particularly restricted provided that it is a pharmaceutically acceptable. Nonrestrictive examples of phospholipid include phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, sphingomyelins, and lecithin. Hydrogenated phospholipids can also be used. The preferred phospholipid includes egg yolk phosphatidylcholine, egg yolk lecithin, soybean lecithin, and egg yolk phosphatide. Two or more different phospholipids can also be used in combination. As to phospholipids to be used with Compound A, phosphatidylcholine and lecithin are superior to phosphatidylethanolamine which is commonly used in the cationic liposome.

In a preferred embodiment, the present invention provides a

pharmaceutical preparation comprising a complex of the carrier wherein the phospholipid is lecithin and a poly(I)•poly(C) having a mean chain length ranging from 100 to 500 bp, especially 200 to 400 bp.

The ratio of the cationic liposome to the double-stranded RNA varies depending on the kind or chain length of cationic liposome or double-stranded RNA, the type or stage of hepatitis, and other factors, but the recommended proportion of the double-stranded RNA relative to 10 weight parts of the cationic liposome is 0.05-10 weight parts, preferably 0.1-4 weight parts, and more preferably 0.5-2 weight parts. Likewise, the recommended proportion of poly(I)•poly(C) relative to 10 weight parts of the carrier is 0.05-10 weight parts, preferably 0.1- 4 weight parts, and more preferably 0.5-2 weight parts.

The ratio of Compound A to the phospholipid in the carrier varies depending on the kind, chain length, and amount of double-stranded RNA and the kind of phospholipid, and other factors, but the recommended proportion of phospholipid relative to each weight part of Compound A is 0.1-10 weight parts, preferably 0.5-5 weight parts, and more preferably 1-2 weight parts.

The agent of the present invention may, for example, be provided in the form of liquid preparation for injection or drip infusion, in which the complex is dispersed in an aqueous solution, or in the lyophilized form. In the case of a liquid preparation, the recommended concentration of the complex is 0.001-25% (w/v), preferably 0.01-5% (w/v), and more preferably 0.1-1% (w/v).

The agent of the present invention may contain any of pharmaceutically acceptable additives, such as an auxiliary emulsifier, stabilizer, isotonizing agent, and/or a pH regulator, in suitable amounts. Specific examples include auxiliary emulsifiers such as C_{12-22}

fatty acids (e.g. caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, arachidonic acid, docosahexenoic acid) or their pharmaceutically acceptable salts (e.g. sodium salts, potassium salts, calcium salts, etc.), albumin, dextran, etc.; stabilizers such as cholesterol, phosphatidine, etc.; isotonizing agents such as sodium chloride, glucose, maltose, lactose, sucrose, trehalose, etc.; and pH regulator such as hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, sodium hydroxide, potassium hydroxide, triethanolamine, etc..

The agent of the present invention can, for example, be prepared in a manner similar to the general technology for the production of liposomes. A typical method comprises dispersing a double-stranded RNA such as poly(I)·poly(C) with a cationic liposome or raw materials thereof (e.g., Compound A and a phospholipid) in an aqueous solution. Examples of the aqueous solution includes, but is not limited to, water for injection, distilled water for injection, electrolyte solution such as physiological saline, or glucose solution. The dispersing treatment can be performed with a suitable dispersing machine such as a homomixer, homogenizer, ultrasonic disperser, ultrasonic homogenizer, high-pressure emulsifier-disperser, Microfluidizer (trade name), Nanomizer (trade name), Ultimizer (trade name), or Manton-Gaulin high-pressure homogenizer. Further, the dispersing treatment can be divided into several steps including, for example, a crude dispersion step.

A commercially available cationic liposome can be used as it is or after appropriate processing.

When the agent of the present invention is prepared from the raw

materials for cationic liposome, the materials and the double-stranded RNA such as poly(I)·poly(C) can be dispersed together. Alternatively, the cationic liposome is first formed by dispersing the materials, and then redispersed after the addition of a double-stranded RNA such as poly(I)·poly(C) to obtain the agent of the present invention.

The pharmaceutically acceptable additives mentioned above can be added at a suitable stage before or after the dispersion.

The agent of the present invention thus prepared by the dispersing procedure may be freeze-dried to provide a lyophilized agent of the present invention. The freeze-drying operation can be carried out in a conventional manner. For example, the agent of the present invention obtained by dispersing procedure is sterilized and distributed into vials at a determined amount. The filled vials are subjected to preliminary freezing at about -40°C to -20°C for about 2 hours and, primary drying in vacuo at about 0°C to 10°C and then to secondary drying in vacuo at about 15°C to 25°C. Generally, the vials are purged with nitrogen gas and stoppered to provide the objective lyophilized agent of the present invention.

The lyophilized agent of the present invention can be generally reconstituted by adding a suitable solvent (for reconstitution) and put to use. The solvent for reconstitution includes water for injection, electrolyte solution such as physiological saline, glucose solution, and other ordinary infusions. The volume of the solvent for reconstitution varies depending on the intended use and is not particularly restricted but may preferably be 0.5-2 times the volume of the agent prior to freeze-drying, or not larger than 500 mL.

The agent of the present invention can accumulate specifically in the liver and spleen, and induce more β -interferon for a long time

than a double-stranded RNA such as poly(I)·poly(C) alone, and is useful in the treatment or prevention of hepatitis in mammals inclusive of man. Particularly, the agent of the present invention which is related to a complex of the carrier comprising lecithin as a phospholipid with poly(I)·poly(C) (mean chain length = 100-500 bp, particularly, 200-400 bp) as a double-stranded RNA is highly efficacious and yet is very low in toxicity.

The agent of the present invention can for example be administered intravenously, transmucosally, or into the hepatic artery.

The dosage of the agent of the present invention in hepatitis therapy varies depending on the kinds of double-stranded RNA and phospholipid, the type of hepatitis, the stage of hepatitis, the recipient's age and animal species, route or mode of administration. In terms of double-stranded RNA, the recommended dosage is usually 1 μ g-50 mg/man, and preferably 10 μ g-10 mg/man per dose. In terms of poly(I)·poly(C), the recommended dosage is usually 1 μ g-50 mg/man, and preferably 10 μ g-10 mg/man per dose. The agent of the present invention can be administered in one shot or by drip injection once through 3 times a day, every day, every other day, or on a weekly or fortnightly basis.

BEST MODE FOR CARRYING OUT THE INVENTION

The following working examples and test examples illustrate the present invention in more detail. It should be understood that the concentration of the agent of the present invention is invariably expressed in the concentration of the poly(I)·poly(C) in the agent.

Example 1

A solution of 40 g of maltose in 100 mL of water for injection was stirred with 2 g of Compound A and 2 g of purified egg yolk lecithin and the mixture was treated with a homogenizer for 5 minutes to prepare

a crude carrier dispersion. This crude dispersion was further treated with a bench-top compact emulsifier-disperser for 1 hour and adjusted to 250 mL with water for injection. The resulting carrier dispersion was recovered. To 250 mL of this carrier dispersion was added 150 mL of an aqueous solution containing 500 mg of poly(I)•poly(C) [mean chain length : about 200 bp] with stirring, and using a bench-top compact emulsifier-disperser, the mixture was further treated for 1 hour to provide the agent of the present invention. This agent was then distributed into vials, 1 mL per vial, and freeze-dried in a conventional manner to provide a lyophilizate.

Example 2

A solution of 4 kg of sucrose in 10 L of water for injection was stirred with 50 g of Compound A and 30 g of egg yolk phosphatide and the mixture was treated with a Manton-Gaulin high-pressure homogenizer for 10 minutes. The resulting dispersion was made up to 25 L with water for injection and recovered. To 20 L of this carrier dispersion was added 12 L of an aqueous solution containing 10 g of poly(I)•poly(C) [mean chain length : about 200 bp] with stirring, and the mixture was adjusted to pH 5.5 with hydrochloric acid and further treated with a Manton-Gaulin high-pressure homogenizer for 30 minutes to provide the agent of the present invention. This agent was then distributed into vials, 20 mL per vial, and freeze-dried in a conventional manner to provide a lyophilizate. This lyophilized preparation was reconstituted by adding a commercial 5% glucose infusion (500 mL).

Example 3

A solution of 20 g of glucose in 100 mL of water for injection was stirred with 2 g of Compound A and 2 g of soybean lecithin and the mixture was treated with a homogenizer for 5 minutes to prepare a crude carrier dispersion. This crude dispersion was further treated

with a bench-top compact high pressure emulsifier-disperser for 1 hour and adjusted to 250 mL with water for injection. The resulting carrier dispersion was recovered. To 250 mL of this carrier dispersion was added 150 mL of an aqueous solution containing 50 mg of poly(I)·poly(C) [mean chain length : about 200 bp] with stirring, and using a bench-top compact high pressure emulsifier-disperser, the mixture was further treated for 1 hour to provide the agent of the present invention.

Example 4

A solution of 40 g of maltose in 100 mL of water for injection was stirred with 1.2 g of Compound A and 2.0 g of purified egg yolk lecithin and this crude dispersion was further treated with a bench-top compact high pressure emulsifier-disperser for 30 minutes and made up to 250 mL with water for injection. The resulting carrier dispersion was recovered. To 250 mL of this carrier dispersion was added 150 mL of an aqueous solution containing 200 mg of poly(I)·poly(C) [mean chain length : about 200 bp] with stirring, and using a bench-top compact high pressure emulsifier-disperser, the mixture was further treated for 2 hours to provide the agent of the present invention.

Example 5

A solution of 40 g of maltose in 100 mL of water for injection was stirred with 1.2 g of Compound A and 2.0 g of purified egg yolk lecithin and this crude dispersion was further treated with a bench-top compact high pressure emulsifier-disperser for 30 minutes and made up to 250 mL with water for injection. The resulting carrier dispersion was recovered. To 250 mL of this carrier dispersion was added 150 mL of an aqueous solution containing 100 mg of poly(I) [mean chain length : 360 base] and 100 mg of poly(C) [mean chain length : 318 base] with stirring, and using a bench-top compact high pressure emulsifier-disperser, the mixture was further treated for 2 hours to provide the agent of the present invention.

Example 6

A solution of 40 g of maltose in 100 mL of water for injection was

stirred with 2 g of Compound A and 2 g of purified egg yolk lecithin and the mixture was treated with a homogenizer for 5 minutes to prepare a crude carrier dispersion. This crude dispersion further treated with a bench-top compact high pressure emulsifier-disperser for 1 hour and adjusted to 250 mL with water for injection. The resulting carrier dispersion was recovered. To 250 mL of this carrier dispersion was added 150 mL of an aqueous solution containing 250 mg of poly(I) [mean chain length : 1419 base] and 250 mg of poly(C) [mean chain length : 1491 base] with stirring, and using a bench-top compact high pressure emulsifier-disperser, the mixture was further treated for 1 hour to provide the agent of the present invention. This agent was then distributed into vials, 1 mL per vial, and freeze-dried in a conventional manner to provide a lyophilizate.

Example 7

A solution of 40 g of maltose in 100 mL of water for injection was stirred with 1.2 g of Compound A and 2.0 g of purified egg yolk lecithin and this crude dispersion was further treated with a bench-top compact high pressure emulsifier-disperser for 30 minutes and made up to 250 mL with water for injection. The resulting carrier dispersion was recovered. To 250 mL of this carrier dispersion was added 150 mL of an aqueous solution containing 100 mg of poly(I) [mean chain length : 84 base] and 100 mg of poly(C) [mean chain length : 76 base] with stirring, and using a bench-top compact high pressure emulsifier-disperser, the mixture was further treated for 2 hours to provide the agent of the present invention.

Example 8

The agent of the present invention containing poly(I)•poly(C) [mean chain length : about 350 bp] was prepared in the same manner as given in Example 4.

Example 9

The agent of the present invention containing poly(I)•poly(C) [mean chain length : about 1450 bp] was prepared in the same manner as given in Example 4.

Example 10

The agent of the present invention containing poly(I)•poly(C) [mean chain length : about 80 bp] was prepared in the same manner as given in Example 4.

Test Example 1: β -Interferon Induction Effect in Mouse Liver (in vivo)

The agent of the present invention according to Example 4 or poly(I)•poly(C) alone for control was administered by i.v. injection into 3 male mice (Balb/c, 5-week-old). After 3 hours, the livers were collected and total RNA was extracted by the acid-guanidine-phenol-chloroform (AGPC) method. The amount of expressed β -interferon mRNA was determined by RT-PCR. The result is shown in Figure 1.

It is apparent from Figure 1 that every sample expressed β -interferon mRNA and that β -interferon was induced in a dose-depending manner. The agent of present invention induced more β -interferon than that poly(I)•poly(C) alone did.

Test Example 2: β -Interferon Induction Effect in Mouse Tissues Other than Liver (in vivo)

The amount of expressed β -interferon mRNA in mouse tissues other than liver was determined in the same manner as Test Example 1. The result is shown in Figure 2.

It is apparent from Figure 2 that the agent of the present invention did not bring about the expression of β -interferon mRNA or the induction of β -interferon very much in the kidney, lung and brain.

The results of Test Examples 1 and 2 above show that poly(I)•poly(C) alone is not targeted to any specific tissues but the agent of the present invention induces β -interferon very much in the

liver and spleen in particular.

Test Example 3: Amount of Interferon in Mouse Serum (in vivo)

The agent of the present invention according to Example 4 or poly(I)·poly(C) alone for control was administered by i.v. injection into 3 male mice (Balb/c, 5-week-old). After 3 hours, the serum was collected and the interferon level in serum was determined on basis of the inhibitory effect on the degeneration of L929 cells by virus (VSV) infection. The result is shown in Table 1.

Table 1 Interferon Level in Mouse Serum

	dosage (μ g/kg)	Interferon level (IU/ml)
control	-	<3
Example 4	10	13 \pm 2
	30	41 \pm 1
	100	63 \pm 18
poly(I)·poly(C) alone	10	<3
	30	5 \pm 2
	100	18 \pm 6

It is apparent from Table 1 that interferon was detected in serum in a dose-depending manner in every sample, but more interferon was detected in animals received the agent of the present invention.

In animals of a group which received 100 μ g/kg of the agent of the present invention, the interferon level was 63 I.U./ml at 3 hour, and 30 I.U./ml even at 24 hour after the administration. It has been reported that when β -interferon of 3×10^6 I.U. was administered to human clinically, the plasma level of interferon was 67 I.U./ml immediately after the administration, and was not detected after 45 minutes. Therefore, these results indicate that the agent of the present invention can induce clinically enough amount of β -interferon continuously.

Test Example 4: Toxicity Study

(1) Expression of hepatotoxicity in rats after a single dose (acute toxicity study)

To eight male SD rats aged 6 weeks were intravenously injected the agent of the present invention according to Example 4 in a single dose, and the serum aminoacyl transferase level was determined after 20 hours. As a result, no death was observed at doses up to 5 mg/kg, at which dose a slight elevation of serum aminoacyl transferase at most was observed. At 1 mg/kg, the serum aminoacyl transferase level was little elevated.

(2) Two-week limited subacute toxicity study in rats

The agent of the present invention according to Example 4 was administered intravenously to 6 male SD rats (aged 6 weeks) daily for 14 consecutive days. As a result, no remarkable sign of toxicity was found at doses up to 1 mg/kg.

(3) Antigenicity study

Using male guinea pigs (Hartley strain, 5 weeks old), the antigenicity of the agent of the present invention according to Example 4 was studied. As a result, no antigenicity was found at 50 μ g/animal.

(4) Expedient mutagenicity study

The agent of the present invention according to Example 4 was subjected to expedient reverse mutation assay and expedient chromosomal aberration assay. As a result, no mutagenicity was found at 10 μ g/ml.

Brief Description of the Drawings

Figure 1 is a graph showing the amount of β -interferon mRNA expressed in mouse liver. The left end column in the figure represents the control group. The central three columns represent the results obtained in the groups received the agent of the present invention according to Example 4, wherein each column corresponds to a group administered the agent at a dosage of 10 μ g/kg, 30 μ g/kg, and 100 μ g/kg from the left-hand in order. The right end three columns represent the results obtained in the groups received the poly(I)•poly(C) preparation alone, wherein each column corresponds to a group administered the preparation at a dosage of 10 μ g/kg, 30 μ g/kg, and 100 μ g/kg from the left-hand in order. The ordinate

represents the ratio of the amount of β -interferon mRNA expressed in the drug administration groups to that in control.

Figure 2 is a graph showing the amount of β -interferon mRNA expressed in mouse tissues (spleen, kidney, lung, and brain from the top in order). The left end column in each figure represents the control group. The central three columns in the figure for each tissue represent the results obtained in the groups received the agent of the present invention according to Example 4, wherein each column corresponds to a group administered the agent at a dosage of 10 μ g/kg, 30 μ g/kg, and 100 μ g/kg from the left-hand in order. The right end three columns in the figure for each tissue represent the results obtained in the groups received the poly(I)•poly(C) preparation alone, wherein each column corresponds to a group administered the preparation at a dosage of 10 μ g/kg, 30 μ g/kg, and 100 μ g/kg from the left-hand in order. The ordinate represents the ratio of the amount of β -interferon mRNA expressed in the drug administration groups to that in control.

AKZ

[illegible][illegible][illegible][illegible][illegible]

Abstract

The object of the present invention is to provide a novel medicinal agent useful in the treatment or the prevention of hepatitis.

The present invention is, for example, a therapeutic or preventive agent for hepatitis characterized in that it comprises a complex of a drug carrier consisting essentially of 2-O-(2-diethylaminoethyl)-carbamoyl-1,3-O-dioleoylglycerol and a phospholipid with poly(I)•poly(C).




Fig. 1




Fig. 2

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **REMEDIES FOR HEPATITIS** the specification of which is attached hereto unless the following box is checked:

☐ was filed on _____ as United States Application Number or PCT International Application Number _____ and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)	<u>Priority Date</u>	<u>Priority Claimed</u>	
<u>Hei-10/076,055</u> (Number)	<u>Japan</u> (Country) (PCT)	<u>24 March 1998</u> (Day/Month/Year Filed)	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

_____ (Application Number)	_____ (Filing Date)
_____ (Application Number)	_____ (Filing Date)

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

<u>PCT/JP99/01438</u> (Application Number)	<u>23 March 1999</u> (Filing Date)	<u>Pending</u> (Status – patented, pending, abandoned)
_____ (Application Number)	_____ (Filing Date)	_____ (Status – patented, pending, abandoned)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Albert L. Jacobs, Jr.
Jesse D. Reingold
Gerard F. Diebner
Eugene C. Rzucidlo

Reg. No. 22,211
Reg. No. 20,461
Reg. No. 31,345
Reg. No. 31,900

Joseph M. Manak
Adam B. Landa
Mark A. Farley
Alan P. Force

Reg. No. 33,013
Reg. No. 35,236
Reg. No. 33,170
Reg. No. 39,673

Address all correspondence to:

Eugene C. Rzucidlo, Esq.
Intellectual Property Group -
Greenberg Traurig LLP
885 Third Avenue, 21st floor
New York, New York 10022
(212) 848-1000

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor (given name, family name) 1-00 Kazuko HIRABAYASHI

Inventor's signature Kazuko Hirabayashi Date August 16, 2000

Residence Room 307, Greenpalace Kaikonoyashiro 11-1, Uzumasa Citizenship Japan
Morigamaecho, Ukyo-ku, Kyoto-shi, Kyoto 616-8105 Japan SPX

Post Office Address Same as above

Full name of second inventor (given name, family name) 2-00 Junzo SEKI

Inventor's signature Junzo Seki Date August 16, 2000

Residence 13-11, Nishiekimaecho, Ibaraki-shi, Osaka 567-0032 Japan Citizenship Japan JPX

Post Office Address Same as above